Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
5(45%)
Results Posted
50%(1 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
1
9%
Ph phase_3
1
9%
Ph phase_4
3
27%
Ph not_applicable
6
55%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
3(27.3%)
N/ANon-phased studies
6(54.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Completed(2)
Terminated(1)

Detailed Status

Recruiting3
Not yet recruiting3
Active, not recruiting2
Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (9.1%)
Phase 31 (9.1%)
Phase 43 (27.3%)
N/A6 (54.5%)

Trials by Status

recruiting327%
terminated19%
active_not_recruiting218%
completed218%
not_yet_recruiting327%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11